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Abstract 
 
The androgen receptor (AR) is a transcription factor, and key regulator of 
prostate development and cancer, which has discrete functions in stromal versus 
epithelial cells. AR expressed in mesenchyme is necessary and sufficient for 
prostate development while loss of stromal AR is predictive of prostate cancer 
progression. Many studies have characterized genome-wide binding of AR in 
prostate tumour cells but none have used primary mesenchyme or stroma. 
 
We applied ChIPseq to identify genomic AR binding sites in primary human fetal 
prostate fibroblasts and patient derived cancer associated fibroblasts, as well as 
the WPMY1 cell line overexpressing AR. We identified AR binding sites that were 
specific to fetal prostate fibroblasts (7534), cancer fibroblasts (629), WPMY1-AR 
(2561) as well as those common among all (783). Primary fibroblasts had a 
distinct AR binding profile versus prostate cancer cell lines and tissue, and 
showed a localisation to gene promoter binding sites 1kb upstream of the 
transcriptional start site, as well as non-classical AR binding sequence motifs. 
 
We used RNAseq to define transcribed genes associated with AR binding sites 
and derived cistromes for embryonic and cancer fibroblasts as well as a cistrome 
common to both. These were compared to several in vivo ChIPseq and transcript 
expression datasets; which identified subsets of AR targets that were expressed 
in vivo and regulated by androgens. This analysis enabled us to deconvolute 
stromal AR targets active in stroma within tumour samples. 
 
Taken together, our data suggest that the AR shows significantly different 
genomic binding site locations in primary prostate fibroblasts compared to that 
observed in tumour cells. Validation of our AR binding site data with transcript 
expression in vitro and in vivo suggests that the AR target genes we have 
identified in primary fibroblasts may contribute to clinically significant and 
biologically important AR-regulated changes in prostate tissue. 
3 
Introduction 
 
The androgen receptor (AR) is known to be essential for masculinisation of sex- 
accessory reproductive organs such as the prostate, seminal vesicle and penis, 
as well as playing a central role in prostate cancer. 
 
Paracrine signalling mechanisms active in the developing prostate are often 
dysregulated in prostate tumours [1-3]. Stromal-specific secreted molecules 
identified in embryonic rat and human prostate tissues have been shown to be 
re-expressed in cancer-associated fibroblasts (CAFs) and can modulate tumour 
growth [4, 5]. In addition, stromal markers have been shown to correlate with 
disease progression and may be predictors of aggressive prostate tumour 
subtypes [6]. 
 
During development, AR expressed in mesenchymal cells is both necessary and 
sufficient for androgen mediated reproductive development; AR expressed in 
epithelial cells is not required [7, 8]. In prostate cancer, AR functions in both the 
tumour cells and via CAFs. CAFs are known to play an important role in prostate 
tumour growth [9] and AR action within CAFs is able to contribute to hormone 
sensitive tumour growth [10]. In these experiments, AR was absent from the 
tumour cells, demonstrating that hormonal effects upon growth are likely to be 
mediated by AR in CAFs [10]. The function of AR has not been extensively 
examined in mesenchymal or stromal cells, despite their physiological 
importance, and our current knowledge of AR activity is derived from studies in 
prostate cell lines and patient tumour samples. Thus, the current AR cistrome 
reflects AR activity in cells that do not reflect androgen function in vivo during 
development or androgen action in fibroblasts present in prostate cancer stroma. 
 
Recent advances in ChIP sequencing (ChIPseq) and gene profiling technologies 
have enabled the characterization of genome-wide AR binding and the AR 
transcriptional network (reviewed in [11]). The majority of these studies have 
been conducted on prostate cancer cell lines and considerable effort has been 
made in defining AR targets in tumour epithelium [12-17]. This has revealed a 
transcriptional role for AR in tumour cells regulating cell proliferation, metabolism, 
survival and DNA repair [18, 19]. Prostate cancer cell lines have also been used 
to determine the changes in AR transcriptional networks in both a hormone- 
naïve- and castrate-resistant setting and numerous studies have revealed distinct 
binding profiles in the androgen-independent setting [13, 17, 18, 20, 21]. More 
recently, the genomic binding profile of AR variants have also been explored and 
have been shown to compensate for full length AR in an endocrine therapy-like 
setting [22]. These studies have provided valuable insights in to the molecular 
biology and function of the AR and have identified several co-activators and co- 
repressors that modulate AR transcriptional activity [23-28]. 
 
It has been shown that the genome-wide AR binding profiles identified in prostate 
cancer cell line models are not reflective of in vivo tissues and that AR target 
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gene signatures identified in prostate cancer tissues are not represented in 
prostate cancer cell line models [29]. This has highlighted the importance of 
studying AR genomic binding in primary cells or tissues. Therefore, more 
recently, the genomic behavior of AR has been investigated in prostate cancer 
tissues and has revealed that AR genomic binding and interactions are 
reprogrammed with different tumour stages and have prognostic value [30-33]. 
However, tissue samples typically contain multiple distinct cellular components 
and the majority of studies to date have neglected the role of the AR in CAFs 
present in the tumour microenvironment. It has been shown that human prostate 
myofibroblast cell lines have a different AR binding profile to prostate cancer 
epithelium and are not dependent on the classic AR pioneer factors such as 
FOXA1 [34]. The role of AR in stroma is likely to be important, since stromal 
expression of AR is prognostic [35, 36] and the genes regulated by AR in stroma 
may themselves be prognostic and control cell proliferation and differentiation. 
However, no study has addressed the genomic behavior of AR in primary 
prostate developmental or cancer-associated fibroblasts. In addition, the majority 
of studies to date investigating the AR transcriptional network have been limited 
by genome coverage on microarrays and thus may not adequately capture the 
full landscape of AR binding and transcriptional regulation in cells and tissues. 
 
We have applied ChIPseq and RNA sequencing of the transcriptome (RNAseq) 
to provide the first AR cistrome in primary prostate embryonic and cancer- 
associated fibroblasts. In fibroblasts, the AR genomic distribution was distinct 
from prostate cancer cell lines, with a strong enrichment at proximal promoter 
regions of genes and with preference for non-classical AR binding motifs. Genes 
associated with these binding sites correlated well with the fibroblast 
transcriptomes and allowed us to define cancer-fibroblast specific and embryonic 
prostate fibroblast specific AR cistromes. The AR cistromes showed a high 
degree of overlap with transcripts expressed in embryonic prostate tissue and 
prostate cancer stroma. Overall, our study provides the first insight in to the AR 
genomic distribution in both primary developmental and primary cancer- 
associated prostate fibroblasts. 
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Materials and Methods 
 
Cell culture 
Immortalized human prostatic stromal cells overexpressing wildtype AR 
(WPMY1-AR cells) [37] were a gift from Drs M. Grabowska and R. Matusik 
(Vanderbilt University, TN, USA). Primary embryonic prostate fibroblasts (EPF) 
were derived from 12-16 week human embryonic tissue as per [38] in 
accordance with UK guidelines and following approval by the Lothian Research 
Ethics Committee. Primary prostate cancer-associated fibroblasts (CAF) were 
isolated from prostate specimens of patients undergoing radical prostatectomy 
and bioassayed in an in-vivo tissue recombination model to determine their pro- 
tumorigenic potential as previously described [9]. Primary fibroblast cells were 
assessed for the expression of known fibroblast markers from RNAseq data to 
confirm fibroblast identity (Supplementary Table 1). All cells were maintained in 
DMEM supplemented with 10% FBS and used at passages between 5 and 7 for 
all ChIPseq assays. All primary cells were used under ethical approval 15-631- 
MUHC. 
 
For testosterone treatment, WPMY1-AR cells (1 x 106) were plated in 10cm2 
plates and grown overnight. Cells were washed 3 x PBS and medium was 
replaced with DMEM supplemented with 10% charcoal-stripped fetal bovine 
serum ± 10nM, 100nM testosterone (Sigma-Aldrich, Missouri, USA) or ethanol as 
vehicle control, and cells were cultured for 72 hours. 
 
Western blotting 
This was performed using Mini-PROTEAN® TGX Stain-FreeTM Precast Gels (4- 
15%) and proteins transferred to 0.2μm polyvinylidene difluoride membrane 
using the Trans-Blot® TurboTM  Blotting system (Bio-Rad Laboratories, Inc. 
California, USA). Membranes were incubated (4°C overnight) with AR H280 IgG 
(Rabbit Polyclonal, Santa Cruz Biotechnology, Santa Cruz, USA; dilution 
1:1000), ZFX IgG (Rabbit Polyclonal, SAB3501008 Sigma-Aldrich, Missouri, 
USA; dilution 1:800) or β-actin IgG (Clone AC-15, Sigma-Aldrich, Missouri, USA; 
dilution 1:10000) and HRP conjugated secondary antibodies (Jackson 
ImmunoResearch Laboratories, Inc.; dilution 1:10000; 1 hr) before visualisation 
with ClarityTM Western ECL Substrate (Bio-Rad Laboratories, Inc. California, 
USA). 
 
Immunofluorescence staining 
Cells in either full serum medium or cells previously serum starved for 48 hours 
were seeded into sterile multi-chamber slides (Sarstedt AG & Co, Germany) and 
allowed to recover overnight so that 60% confluency was reached. Cells were 
treated with 10nM testosterone in ethanol or ethanol (control) in full serum or 
serum-free media and incubated for 24 hours. Cells were rinsed in PBS and 
fixed/permeabilised for 20 mins in 1:1 ethanol/acetone solution at -20oC. Fixed 
cells were blocked with 1% bovine serum albumin before incubation with AR 
H280 diluted 1:200 in blocking solution for 1 hour at room temperature. Primary 
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antibody was omitted to serve as a negative control. Goat anti-rabbit IgG 
conjugated to Texas Red®-X fluorescent dye (Invitrogen, ThermoFisher 
Scientific, Massachusetts, USA) was applied and incubated in the dark for 40 
mins. Slides were mounted using VECTASHIELD hard-set mountant containing 
4’,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Inc. California, USA) 
and visualized with a Zeiss LSM 780 laser scanning confocal microscope. 
 
Chromatin Immunoprecipitation and sequencing library preparation (Illumina) 
ChIP sequencing was carried out by Active Motif (Carlsbad, CA, USA) as follows. 
Cells were fixed with 1% formaldehyde for 15 min and quenched with 0.125 M 
glycine. Chromatin was isolated by the addition of lysis buffer, followed by 
disruption with a Dounce homogenizer. Lysates were sonicated and the DNA 
sheared to an average length of 300-500 bp. Genomic DNA (Input) was prepared 
by treating aliquots of chromatin with RNase, proteinase K and heat for de- 
crosslinking, followed by ethanol precipitation. Pellets were resuspended and the 
resulting DNA was quantified on a NanoDrop spectrophotometer. Extrapolation 
to the original chromatin volume allowed quantitation of the total chromatin yield. 
An aliquot of chromatin (30 µg) was precleared with protein A agarose beads 
(Invitrogen, ThermoFisher Scientific, Massachusetts, USA). Genomic DNA 
regions of interest were isolated using 4 µg of antibody against AR H280. 
Complexes were washed, eluted from the beads with SDS buffer, and subjected 
to RNase and proteinase K treatment. Crosslinks were reversed by incubation 
overnight at 65 C, and ChIP DNA was purified by phenol-chloroform extraction 
and ethanol precipitation. 
Quantitative real-time PCR reactions were carried out in triplicate on specific 
genomic regions using SYBR Green Supermix (Bio-Rad Laboratories, Inc. 
California, USA). The resulting signals were normalized against Input DNA for 
primer efficiency according to the Active Motif ChIP-IT® qPCR analysis kit 
protocol. 
Illumina sequencing libraries were prepared from the ChIP and Input DNAs by 
the standard consecutive enzymatic steps of end-polishing, dA-addition, and 
adaptor ligation. After a final PCR amplification step, the resulting DNA libraries 
were quantified and sequenced on Illumina’s NextSeq 500 (75 nt reads, single 
end). 
 
ChIP sequence read and peak analysis 
Reads were aligned to the human genome (hg19) using the Bowtie2 algorithm 
(default settings) [39]. Duplicate reads were removed and only uniquely mapped 
reads (mapping quality >= 25) were used for further analysis. AR peak locations 
were determined by comparing with input samples using the MACS v2.0.10 
algorithm [40] with a cutoff of p-value = 1e-7 and the HOMER findPeaks 
algorithm (default settings). Only peaks that were co-identified by both algorithms 
were used for further analysis. Overlap, feature annotation, peak characterization 
and enriched motif analysis (de novo) were performed using the HOMER suite of 
algorithms [41]. Known motif analysis was also performed using MEME [42] with 
the JASPAR 2016 database [43]. The deepTools suite of algorithms [44] were 
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used to determine sample similarity by hierarchical clustering and Spearman 
correlation and for ChIPseq read enrichment analysis around specific peak sites. 
All size proportional Venn diagrams were created using BioVenn [45]. For 
prostate cancer in vitro cell line (PCCL) datasets, only cell lines which contained 
androgens in their culture media were selected for analysis. PCCL and prostate 
cancer in vivo datasets of AR binding sites were generated by combining AR 
peak regions (if reads were aligned to hg19 and peaks called with MACS2 or 
HOMER) or by re-analzying raw ChIP-seq read sequences as above with 
publicly available ChIP sequencing datasets detailed in Supplementary Tables 2 
and 11. Visualization of ChIPseq read coverage was performed using IGB 
software [46]. 
 
RNA extraction and quantitative real-time PCR 
Total RNA was extracted using Qiazol followed by the RNeasyTM Mini kit (Qiagen, 
Venlo, Netherlands) following manufacturers instructions. Complementary DNA 
synthesis was performed using the High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems- ThermoFisher Scientific, Massachusetts, USA) and 
qPCR was performed on an ABI 7500 Fast machine using SYBR Select 
Mastermix (ThermoFisher Scientific, Massachusetts, USA). Transcript 
abundance was normalized to two housekeeping genes; RPLP0 and EIF2B1. 
Primers used are provided in Supplementary Table 3. 
 
Immunohistochemistry 
Immunostaining of AR and ZFX on serial sections of male rat P0 urogenital tract 
tissue (isolated as per [38]) was performed using AR H280 IgG (Rabbit 
Polyclonal, Santa Cruz Biotechnology, Santa Cruz, USA; dilution 1:800) and ZFX 
IgG (Rabbit Polyclonal, HPA003877 Sigma-Aldrich, Missouri, USA; dilution 
1:1500). Primary antibody was omitted to serve as a negative control. Tissue was 
de-paraffinised in xylene and hydrated in ethanol and rinse under water. Antigen 
retrieval was performed by pressure cooking in 0.2M citrate buffer, pH 6.0 (Poly 
Scientific R&D Corp, Bay Shore, NY, USA) for 10 min. Endogenous peroxidase 
activity was blocked for 30 min with 3% H2O2. After a 3 h block with IHC Select 
(Millipore, Billeria, MA, USA), the primary antibody was used overnight at 4°C. 
Histofine Simple Stain MAX PO multi (Nichirei BioSciences, Inc., Tokyo, Japan) 
was used as secondary antibody and chromogenic detection was carried out 
using Simple Stain AEC Solution (Nichirei BioSciences, Inc.). Images were taken 
with an Aperio Slide Scanner (Leica, Wetzlar, Germany). 
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RNA sequencing library preparation 
RNA sequencing was carried out by Exiqon, Inc (Denmark) as follows. 
Libraries were prepared using a TruSeq® stranded total RNA sample preparation 
kit with rRNA depletion (Illumina, Inc, San Diego, USA). 
100 ng of total RNA was used for library construction and rRNA was depleted 
using biotinylated, target-specific oligos combined with Ribo-Zero rRNA removal. 
The isolated mRNA was subsequently fragmented using enzymatic 
fragmentation. Then first strand synthesis and second strand synthesis were 
performed and the double stranded cDNA was purified (AMPure XP, Beckman 
Coulter). The cDNA was end repaired, 3’ adenylated and Illumina sequencing 
adaptors ligated onto the fragments ends, and the library was purified (AMPure 
XP). The mRNA stranded libraries were pre-amplified with PCR and purified 
(AMPure XP). The libraries size distribution was validated and quality inspected 
on a Bioanalyzer high sensitivity DNA chip (Agilent Technologies). High quality 
libraries were quantified using qPCR, the concentration normalized and the 
samples pooled according to the project specification (number of reads). The 
library pool(s) were re-quantified with qPCR and optimal concentration of the 
library pool used to generate the clusters on the surface of a flowcell before 
sequencing on Nextseq500/ High Output sequencing kit (51 cycles according to 
the manufacturer instructions (Illumina Inc.). 
 
RNA sequence read analysis 
Sequencing reads were aligned to the human genome (hg19) using the Tophat 
2.1.0 algorithm [47] and only uniquely mapped, non-redundant reads were used 
for further analysis. Read counts were quantified with the featureCounts 
algorithm [48] and reads with a transcripts per million (TPM) frequency greater 
than ten were retained. 
 
Tag sequence read analysis 
Tag sequencing expression data from human embryonic prostate tissue from a 
previously published study from our group were re-analysed [5]. Briefly, tag 
sequences were aligned to the human genome (hg19) using the Bowtie2 
algorithm (default settings) and only uniquely mapped, non-redundant reads 
were used for further analysis. Read counts were quantified with the 
featureCounts algorithm [48] and reads with a reads per million (RPM) frequency 
greater than six were retained. 
 
Microarray analysis 
Microarray raw data for three publically available datasets (GSE20758, GSE8218 
and GSE17951) were uploaded from GEO (NCBI) [49] and normalized using 
robust multi-array Averaging (RMA) [50] and batch corrected using Combat [51]. 
Differentially expressed genes between epithelial and stromal samples were 
identified using limma package [52, 53]. Only genes with adjusted p value < 0.05 
were used for comparison to cistromes. GSE20758 contains microdissected 
stromal and epithelial tissue from cancer tissue. With dataset GSE8218 and 
GSE17951, the authors provide cell-type composition estimated by pathologists. 
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For dataset GSE8218, samples from cancer patients with stromal content greater 
then 90% have been compared to samples with tumour content greater then  
70%. For data set GSE17951, samples from cancer patients with tumour content 
equal to 0 were compared to samples from cancer patients with tumour content 
higher then 65%. Expression matrix (normalised and log transformed data) for 
dataset GSE70758 and GSE72920 as provided by the authors in GEO were  
used to identify differentially expressed transcripts in cancer tissues or normal 
tissues treated with a GnRH antagonist (Degarelix) vs non-treated tissues. All 
bioinformatics and statistical analysis were conducted in R and Bioconductor 
suite (http://www.r_project.org) [54]. 
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Results 
 
To establish the AR protein levels present within the primary cells used for 
ChIPseq studies, we performed western blotting with the AR H280 antibody 
(Figure 1A). This showed that AR levels in EPF and CAF were lower than tissue 
in vivo (rat prostate and epididymis) and over 100 fold lower than AR levels 
observed in LNCaP and WPMY1-AR cells. Immunofluorescence staining showed 
heterogeneous expression of AR in WPMY1-AR and CAFs and a shift from 
cytoplasmic to nuclear distribution in response to testosterone (T) in serum-free 
medium in CAFs (Supplementary Figure 1) using AR H280. Due to the response 
to T coupled with the fact we did not observe any isoforms or truncations of the 
AR on our blots using AR H280, we subsequently used this antibody for ChIP 
analysis of AR. ChIP was performed using EPF, CAF and WPMY1-AR cells, 
followed by qPCR analysis of selected AR targets to verify the success of the 
immunoprecipitation prior to full sequencing of the libraries.  We saw enrichment 
of AR binding events associated with a known AR target gene ATAD2 [55] and 
the ARL8B gene in EPF and CAF cells with a ~8 fold and ~30-45 fold range of 
enrichment respectively. Enrichment of AR binding events associated with the 
known AR target gene ZBTB16 [28, 56] was also seen in WPMY1-AR cells with a 
16 fold enrichment (Supplementary Figure 2). This suggested that, despite low 
AR levels in EPF and CAF, we were able to detect AR binding events to 
chromatin in fibroblasts. We were unable to use established AR target genes 
such as PSA since these were derived in epithelial cell types, and are not 
expressed in fibroblasts. 
 
We observed differences in the numbers of peaks defined following ChIPseq and 
peak calling with both MACS (2.1.0) and HOMER; WPMY1-AR, EPF and CAF 
yielded 5495, 11120, and 2311 peaks, respectively (Figure 1B, Supplementary 
Table 4) and demonstrated enrichment at ATAD2 and ZBTB16 control gene 
regions (Supplementary Figure 3). WMPY1-AR cells were included as a positive 
control, since we were unsure that our primary cells expressed sufficient AR to 
yield reliable data. The peak number observed following ChIPseq showed no 
relationship with the level of AR expression within the samples used. Indeed, the 
numbers of peaks observed in EPF were double that observed in WPMY1-AR 
cells – yet EPF expressed approximately 100 fold less AR protein than WPMY1- 
AR (Figure 1A). 
 
When peaks were mapped to the genome and annotated with genomic features, 
we observed that an unusually high proportion were associated with proximal 
gene promoter regions; defined as within +100bp and -1Kb of the transcriptional 
start site (TSS) (Figure 1C). EPF, CAF and WPMY1-AR showed 37% (4061), 
41% (948), and 33% (1834) of total peaks associated with promoters. Given that 
the size defined as the proximal promoter was small (1.1Kb) such a high 
frequency of binding sites seems unlikely to occur by chance. Comparison of 
EPF, CAF and WPMY1-AR peaks defined 783 common to all 3 cell types (Figure 
1D). Lists of EPF, CAF and WPMY1-AR peaks along with those that are specific 
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or intersect are provided in the Supplementary data file. We selected candidate 
AR target genes that were associated with an AR peak upstream from the 
transcriptional start site (TSS) in at least 2 cell types. We assessed if these 
(along with AQP3, a known stromal androgen-regulated transcript) were 
androgen-regulated by quantifying their expression by qPCR following treatment 
with T in WPMY1-AR as per [37] (Supplementary Figure 4). We saw that T 
induced a transcriptional response in all 5 candidates suggesting our ChIPseq 
datasets contain target genes that are androgen-regulated. 
 
 
Since WMPY1-AR cells were both immortalised and expressed supra- 
physiological levels of AR, we chose to focus upon data derived from primary 
EPF and CAF. Using correlational analysis, we compared normalized ChIPseq 
read counts in EPF and CAF to each other, as well as to a dataset comprised of 
several publicly available AR ChIPseq binding profiles from a panel of prostate 
cancer cell lines (PCCLs) stimulated with androgens (summarised in 
Supplementary Table 2). Our goal was to define whether the ChIPseq peaks in 
our two primary fibroblasts showed a conserved fibroblast-specific pattern that 
was distinct from that in PCCLs. Figure 2A shows a higher correlation between 
EPF and CAF than either of these versus PCCLs. The mean ChIPseq read 
coverage of peaks common to PCCLs at EPF and CAF peaks was low (Figure 
2B). Similarly, the mean ChIPseq read coverage of EPF and CAF was low at 
PCCL peaks (Supplementary Figure 5). This indicates that tumour cell AR 
exhibits a distinct binding profile from that of AR in fibroblasts. The genomic 
locations of peaks within the PCCL dataset are shown in Figure 2C. In PCCL 
there was a low (2.2%) proportion of peaks in proximal promoter regions, in 
contrast to the high frequency of proximal promoter peaks (30-40%) observed in 
fibroblasts (Figure 2C). To illustrate enrichment of ChIPseq reads relative to the 
transcriptional start site (TSS), read density per peak was plotted for EPF, CAF 
and PCCL datasets, and showed a 2-3 fold enrichment in both EPF and CAF 
relative to PCCL (Figure 2D). We compared peaks identified in EPF, CAF and 
PCCL to define those peaks common to fibroblasts (EPF and CAF) as well as 
specific to fibroblasts (those observed in both EPF and CAF but absent from 
PCCL). In general, there was a very small overlap between the fibroblasts and 
PCCL (131, 56, and 18 peaks among datasets of 11120, 37156 and 2311 
peaks). We observed 1467 peaks that were specific to fibroblasts (and absent in 
PCCL) and common between EPF and CAF (Figure 2E). Lists of specific and 
intersecting EPF, CAF and PCCL peaks are provided in the Supplementary data 
file. 
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Having identified significant numbers of peaks in fibroblasts, we next examined 
whether these might be associated with actively transcribed genes. We 
performed RNAseq on the same samples used for our ChIPseq studies, to 
measure mRNA expression at genome-wide resolution. Comparison of the peaks 
in EPF and CAF (following removal of those common to PCCLs) identified 9466 
EPF-specific peaks, 770 CAF-specific peaks and 1467 peaks shared between 
EPF and CAF (Figure 3A). Examples of peaks specific to EPF or CAF, and 
common to both (Fibroblast), are shown in Figure 3B. Construction and 
sequencing of libraries of EPF and CAF identified 8334 and 6177 mRNAs with a 
read count of > 10 transcripts per million (>10 TPM) in EPF and CAF respectively 
(Figure 3C). To derive cistromes for EPF, CAF and fibroblasts, we selected 
peaks mapped within a 100Kb genomic window 5’ to the TSS, and compared 
these to transcript expression defined by RNAseq. For CAF, 770 CAF-specific 
peaks yielded 308 peaks within 100Kb of the TSS, while 9466 EPF-specific 
peaks yielded 3580 promoter peaks, and the 1467 peaks common to fibroblasts 
yielded 565 promoter peaks. These were then compared with the RNAseq 
defined transcriptomes to derive the EPF, CAF and fibroblast AR cistromes. This 
identified 1560 genes in EPF, 112 genes in CAF, and 208 genes in fibroblasts 
with an associated promoter AR peak (Figure 3D). Gene ontology analysis of the 
cistromes are presented in Supplementary Tables 5-10 and show enrichment of 
ubiquitin-transferase activity, RNA binding and glucocorticoid activity in EPF- 
specific, CAF-specific and fibroblast cistromes respectively. Lists of EPF-specific, 
CAF-specific and fibroblast peaks and cistromes along with lists of transcripts > 
10 TPM from RNAseq are provided in the Supplementary data file. 
 
We evaluated the relative position of peaks to the TSS to examine whether there 
was non-random distribution of peaks in promoters (100Kb 5’ to TSS), and 
observed a striking localisation to sequences immediately adjacent to the 
TSS. Figure 4A shows the distribution of peaks across 100Kb located 5’ of the 
TSS, divided into a series of 20Kb subregions. We included two subregions that 
were not 20Kb in size; one was a 1Kb region directly adjacent to the TSS 
(proximal promoter) and the other was the region furthest from the TSS which 
was defined as 100Kb and greater. Graphs of peaks validated by transcript 
expression are shown in Figure 4B. We plotted both peaks as well as those 
validated by transcript expression, in order to observe possible artefacts 
associated with gene expression or mapping. We determined that the number of 
peaks that are associated with expressed transcripts is not dependent on the 
distance 5’ to the TSS (Supplementary Figure 6) since peak validation by 
transcript data was approximately equal in all regions. We observed that there 
was a very high association of peaks in the proximal promoter regions of EPF, 
CAF and fibroblasts. A similar pattern of proximal promoter peaks was observed 
in WPMY1-AR cells, though this fibroblast cell line expresses 100 fold more AR 
than primary EPF or CAF, and we suggest that AR level does not influence 
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promoter binding location. The proximal position of peaks observed in fibroblasts 
was in marked contrast to PCCL where few peaks were observed in the proximal 
promoter region, but which showed a greater number of peaks in the 100Kb+ 
group. A dataset comprised of several publicly available AR ChIPseq binding 
profiles from a panel of prostate cancer tissues (PCa in vivo, summarised in 
Supplementary Table 11) showed a distribution of peaks similar to PCCL, though 
with some increase in proximal promoter peaks (Figure 4A). We speculate that 
these proximal promoter peaks may arise from the stromal component present 
within the tissue used for ChIP analysis. Enrichment of peaks in the proximal 
promoter region of genes was conserved in our transcript valid peaks 
with 37.5%, 28.3% and 34.2% of 5’ peaks in EPF, CAF and Fibroblasts 
respectively (Figure 4B). To investigate whether AR bound at proximal promoter 
sites might be involved in transcriptional activation or repression, we examined 
the transcript levels for genes with AR peaks in EPF and CAF. This illustrated the 
distribution of transcript levels and showed that a high proportion of AR sites 
were associated with low transcript levels, and we also observed a few AR sites 
associated with abundantly expressed transcripts (Supplementary Figure 7). This 
association is of value in distinguishing the general balance between activation 
and repression, however it does not provide definitive proof of regulation. 
 
Next we addressed whether our AR targets are represented in other published 
datasets. First we compared to in vitro ChIPseq and gene expression microarray 
data of an immortalised prostate fibroblast cell line that overexpresses AR 
(PShTERT-AR) [34]. We observed little overlap between our EPF, CAF and 
WPMY1-AR fibroblast AR peaks with PShTERT-AR peaks. Less than 10% of our 
EPF and CAF promoter-bound cistromes were co-identified in the PShTERT-AR 
cistrome (Supplementary Figure 8). 
We then evaluated whether EPF-specific, CAF-specific and fibroblast-specific 
peaks and cistromes were physiologically relevant by comparing to in vivo tissue 
datasets. Comparisons of EPF-specific, CAF-specific and fibroblast peaks to 
PCa in vivo AR ChIPseq peaks (Supplementary Table 10) co-identified 2021 
(21%), 171 (22%) and 452 (30%) peaks with PCa in vivo tissue respectively 
(Figure 5A). We examined whether the primary fibroblast cistromes were 
associated with actively transcribed genes expressed in human tissue in vivo. 
We first compared EPF-specific, CAF-specific and fibroblast cistromes to the 
genome-wide transcriptome of human embryonic prostate tissue (EMB 
transcriptome, Figure 5B,[5]). This showed a high degree of overlap (83-86%) 
with EMB transcripts suggesting our primary fibroblast cistromes are well 
conserved in developing human prostate in vivo. We then compared our 
cistromes to prostate cancer patient transcripts, and particularly datasets in 
which the stromal proportion of samples were defined. We generated three 
datasets of stromal-specific or stromal-enriched transcripts that were significantly 
upregulated in prostate cancer tissue microarrays compared with tumour 
epithelium. The first dataset consisted of laser-capture microdissected prostate 
cancer stroma vs epithelium yielding 876 stroma-specific transcripts (GSE20758 
[57]). Following removal of transcripts from our cistromes that were not present 
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on the microarrays, comparison to our EPF-specific, CAF-specific and fibroblast 
cistromes identified 111 (12.9%), 4 (7.8%) and 7 (6.1%) transcripts respectively 
which were stromal-specific in prostate cancer in vivo (Figure 5C). The second 
and third datasets consisted of microarray expression data of prostate cancer 
tissue with known stromal and epithelial content; defined by pathologist. Stromal- 
enriched transcripts were determined by comparing samples with high stromal- 
content and low epithelial content versus samples with high epithelial content and 
low stromal content. Transcripts that were significantly upregulated in high 
stroma samples were considered stromal-enriched. These yielded 557 and 5653 
stromal-enriched transcripts (GSE8218 and GSE17951 [58]). Comparison of 
these with our cistromes (following removal of transcripts not present on the 
arrays) yielded 61 (4.8%) and 477 (32.1%) EPF-specific, 6 (7.0%) and 32 
(31.4%) CAF-specific and 7 (4.0%) and 59 (30.1%) fibroblast transcripts which 
are stromal-enriched in prostate cancer in vivo (Figure 5C). Lists of all transcripts 
that intersected with EPF-speciifc, CAF-specific and fibroblast cistromes are 
provided in the Supplementary Data file. 
 
In order to determine whether our cistromes represented androgen-regulated 
targets in vivo, we compiled a list of differentially regulated transcripts in 
response to testosterone in an embryonic mouse model of androgen treated 
urogenital sinus [3]. Comparisons of EPF-specific, CAF-specific and fibroblast 
cistromes to these transcripts co-identified 188 (12.1%), 14 (12.5%) and 20 
(9.6%) with androgen-regulated transcripts respectively (Figure 6A). Next we 
compiled a list of differentially expressed transcripts between non-treated and 
androgen-deprivation treated (ADT) human prostate cancer samples and benign 
adjacent to prostate cancer tissue samples in order to define AR regulated 
transcripts in vivo (GSE72920 and GSE70768 [59]). Comparisons of EPF- 
specific, CAF-specific and fibroblast cistromes to these transcripts showed a 
larger overlap with ADT treated benign adjacent tissue transcripts (11-13%) than 
prostate cancer tissue transcripts (5-6%) (Figure 6B). Lists of all transcripts that 
intersected with EPF-speciifc, CAF-specific and fibroblast cistromes are provided 
in the Supplementary Data file. 
 
Overall, comparison of our cistrome data with transcript expression data derived 
from tissues verified that a high proportion of our experimentally defined AR 
targets were genes expressed in vivo; especially in regard to prostate 
development and also in regard to prostate tumour stroma. 
 
Having identified that AR has a different binding distribution across the genome 
compared to PCCLs, we then addressed whether the DNA sequences which 
stromal AR binds to also differ. We performed de novo motif analysis on EPF, 
CAF and WPMY1-AR peaks using HOMER. We identified DNA sequence motifs 
that were significantly enriched in EPF and WPMY1-AR and we observed that 
these differed from the classical androgen-response element (AREs) reported for 
epithelial cells (Figure 7A). HOMER provided a series of transcription factors with 
a DNA binding motif most similar to the enriched motif. For EPF and CAF, to 
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validate the identified transcription factor motifs, we chose the best matching 
transcription factor with an expression read count of > 10 transcripts per million 
RNAseq data. For WPMY1-AR, we chose the transcription factor with the highest 
match score from HOMER. We identified that ZFX was the most probable 
transcription factor associated with EPF peaks, SWI5 as the most probable 
transcription factor in CAF and ATF3 as the most probable transcription factor in 
WPMY1-AR (Figure 7B). Motif analysis was also performed using the MEME 
algorithm [42] which identified REST as the most probable transcription factor for 
both EPF and CAF which reached statistical significance in EPF only 
(Supplementary Table 12). We note that the MEME algorithm does not allow 
analysis of the whole peak dataset for each sample and only a 60bp fraction of 
each peak is considered in the analysis that could account for differences 
between MEME and HOMER. 
We compared the number of ARE positive peaks in our stromal cells vs PCCLs 
and PCa in vivo tissues. We observed ~100 fold less ARE positive peaks in our 
primary stromal cells and ~10 fold less ARE positive peaks in our WPMY1-AR 
than PCCLs. PCa in vivo tissues contain ~4 fold less ARE positive peaks than 
PCCLs (Figure 7C). 
In order to address if ZFX was a potential AR co-factor in developing prostate 
mesenchyme in vivo, we performed immunohistochemistry for AR and ZFX on 
serial sections of male P0 rat urogenital tract tissue (Figure 7D). We observed 
that AR expression is nuclear and largely restricted to mesenchymal cells of the 
developing ventral prostate (VPM) with little or no expression in the epithelial 
cells of the ventral prostatic buds (VPE). ZFX was detected in both the VPM and 
VPE but we observed more nuclear expression in the AR positive VPM and more 
cytoplasmic staining in the AR low/negative VPE. Western blot analysis of ZFX 
also confirmed expression in our in vitro stromal cells as well as LNCaP and PC3 
PCCLs and suggested a mix of nuclear and cytoplasmic expression (determined 
as per [60]) that is not influenced by the levels of AR expression (Supplementary 
Figure 9). 
 
Overall, we have determined that primary prostate stromal cells have a different 
AR binding profile to prostate cancer epithelial cells both in genomic distribution 
and in specific DNA binding sequences. This suggests that stromal AR may co- 
operate with different co-factors, with ZFX being a potential AR co-factor in 
developing prostate. 
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Discussion 
 
We have performed a genome wide analysis of AR binding in primary prostate 
embryonic fibroblasts and cancer associated fibroblasts, and derived AR 
cistromes using RNAseq-based transcript expression data. Fibroblasts and 
stroma play key roles in regulating prostate development and cancer, yet the role 
of AR in these cells has received little investigation, despite their physiological 
importance. 
 
We observed that AR showed a unique genomic distribution in regard to the 
genes and promoter locations occupied in fibroblasts compared to tumour cells. 
This has been shown in a previous study using the PShTERT-AR myofibroblast 
cell line [34]. There was little overlap between our AR peaks and those of 
PShTERT-AR which could be attributed to differences between primary and 
immortalized cell cultures and differences in experimental approaches. In 
particular, the proportion of peaks located close to the TSS was very high in our 
fibroblasts and consisted of approximately 33-40% of all peaks observed. The 
high proportion of promoter bound sites in primary fibroblasts was in marked 
contrast to the location in PCCL or prostate cancer in vivo where approximately 
2% of AR sites were located in gene promoters. The fibroblast promoter peaks 
that we observed were located within 1kb of the TSS, a very small and well 
defined genomic region, and we suggest that this is unlikely to arise by chance or 
random distribution. The location of the peaks in close proximity to the TSS 
suggests that we can be confident of the involvement of AR in the regulation of 
these genes, in contrast to distally located ‘enhancer’ type binding sites that may 
be over 100kb from the TSS which are difficult to assign to the regulation of any 
particular gene. AR binding sites within 1kb of the TSS are likely to play a role in 
gene expression, and we correlated these binding sites with transcript expression 
levels (Supplementary Figure 7). This identified genes with proximal promoter AR 
binding sites and high or low mRNA levels; enabling a general comparison of 
activation versus repression. We observed that there were many AR sites 
associated with low transcript levels and a few with high transcript levels in both 
EPF and CAF. Although we provide some evidence of androgen regulation of 
some of our candidate AR target genes in WPMY1-AR cells (Supplementary 
Figure 4), and through comparisons to published data for androgen-stimulated 
PShTERT-AR cells (Supplementary Figure 8, [34]), we are yet to experimentally 
address transcript response to androgens of our target genes in EPF and CAF 
cells and to determine if our genes with proximal promoter AR binding sites are 
activated or repressed by AR. 
 
The AR protein level in primary fibroblasts was substantially lower than in LNCaP 
or WPMY1-AR cells as well as prostate tissue, and also showed heterogeneity 
among cells in culture (Figure 1 and Supplementary Figure 1). At the inception of 
this work, we were concerned that such low AR levels might not yield sufficient 
peak numbers, which led us to include WMPY1-AR cells engineered to express 
high levels of AR. Interestingly, the peak distribution among EPF, CAF and 
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WPMY1-AR showed considerable overlap (Figure 1), and also showed 
enrichment at proximal promoter sites (Figure 4), despite the considerable 
difference in AR levels between the primary fibroblasts (low) and WPMY1-AR 
cells (100 fold higher). We speculate that the fibroblast signature of AR is 
independent of AR expression level. It is also interesting to note that CAF and 
WPMY1-AR cells show a heterogeneous pattern of AR expression, similar to the 
heterogeneous expression of AR in human prostate stroma – in both 
development and cancer. The ChIPseq peaks derived from these cells must be 
considered to be an ‘average’ of a population made up of cells with different AR 
levels. This issue may also be relevant to AR studies in tumour cells, however 
most published ChIPseq studies have not addressed the expression level or 
heterogeneity of AR. It has been shown that supra-physiological changes in AR 
protein level can affect transcriptional programs in tumour epithelial cell lines [61]. 
We suggest that analysis of AR binding in cells with uniform high or low AR 
expression may be important to precisely define the role of AR level and genomic 
distribution in fibroblasts. 
 
We observed varying proportions of overlap when we compared the AR 
cistromes with transcript datasets derived from tissues in vivo. In general, we 
have used transcript expression to validate and refine our AR peak data, with an 
emphasis on primary cells and tissue expression. The strongest overlap was 
observed when our AR cistromes were compared to fetal prostate tissue [5], 
which may reflect the fact that fetal human prostate is comprised of a high 
proportion of mesenchyme (relative to epithelia), is actively growing, and likely 
shows less cellular heterogeneity than adult tissue. A low proportion of overlap 
was observed between AR cistromes and prostate cancer tissue. In such 
comparisons we predict that the stromal AR cistrome would match transcripts 
expressed in the stroma that comprises a small proportion of the samples. 
However, stroma is of heterogeneous cellular composition, and the extent of this 
heterogeneity is not fully defined. We would expect little overlap between the 
fibroblasts cistromes and tumour cell specific transcripts, since tumour epithelial 
AR peaks were removed from our AR cistromes (Figure 2). To further refine the 
AR cistromes, we compared them with tissue-based datasets derived from 
samples with known stromal content. This showed relatively low overlap with one 
stromal dataset (GSE20758, [57]) but stronger overlap with another 
(GSE8218/GSE17951 [58]), and may show low similarity due to the cellular 
heterogeneity inherent within tumour stroma. In addition, it has been shown that 
stromal AR expression is decreased with increasing grade of prostate tumour 
[35, 36] and therefore a larger dataset comprised of prostate tumours with 
microdissected stroma and sufficient numbers of lower grade tumours would be 
required to formally address this. In all comparisons, we observed a higher 
degree of overlap of EPF-specific targets with PCa stromal-specific/enriched 
transcripts than CAF-specific targets. This may reflect the larger peak number in 
EPF compared to CAF, and perhaps lower cellular heterogeneity in 
developmental versus adult fibroblasts. Additionally, our CAFs represent one 
prostate cancer patient subtype with appreciable levels of AR expression. 
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Patients with an AR positive stroma have a better outcome than those with loss 
of AR [35,62,63]. The PCa data may be enriched for AR negative stroma, due to 
inclusion of higher stage and grade, which would contribute to a lack of overlap 
with our CAF-specific (AR positive) cistrome. Nevertheless, our comparisons 
with EPF-specific and fibroblast cistromes indicate a subset of our stromal AR 
targets are expressed in tumour stroma in vivo and such genes may have 
prognostic potential in prostate cancer. 
 
To define which genes may be AR targets in vivo, we compared our fibroblast AR 
cistromes to datasets addressing androgen regulation in vivo - in both 
development and cancer. We observed an overlap of 9-12% between fibroblast 
cistromes and transcripts regulated by testosterone in urogenital sinus 
development in vivo [3]. There was a similar proportion of overlap when fibroblast 
cistromes were compared with benign-adjacent human prostate undergoing 
androgen deprivation (11-13%); though in this dataset there will be varying 
proportions of stroma and changes in cellular composition in response to 
androgen deprivation. It is also uncertain whether developmental growth that is 
stimulated by androgens bears any similarity to the regression of adult prostate, 
and in either case true gene regulation must be distinguished from changes in 
cell proportions. When stromal cistromes were compared to patient tumour tissue 
undergoing androgen deprivation, there was a lower overlap (6-8%), which may 
reflect the lower proportion of stroma present in cancer samples. In general, 
comparisons of our cistromes with in vivo data will be limited by the fact that the 
proportion of stroma within the tissue can be low, and will change in response to 
hormonal conditions. This limitation notwithstanding, such comparisons provide a 
method to parse large datasets in order to identify those genes that may be of 
physiological importance. It remains possible that such genes will be missed, if 
they are expressed in small subsets of cells present at low proportions within the 
sample (eg stem cells). Comparison with cancer-based datasets is most subject 
to high levels of cellular heterogeneity and this will lead to considerable random 
associations as well as low overlap. We suggest that developmental systems are 
less subject to these particular artefacts. 
 
Analysis of the binding sequences present in the AR-derived peaks showed that 
classical palindromic ARE sequences were very poorly represented in 
fibroblasts, which suggests that the AR is likely to bind to chromatin via co- 
factors or other transcription factors [20]. AP1 was identified as a co-factor for AR 
in the PShTERT-AR cell line [34], however we did not observe many AP1 sites in 
our data. In this study, we have used primary fibroblasts which could account for 
this difference as it has been shown that the AR binding profiles can differ 
between cell lines and primary cells and tissues [29]. The most commonly 
identified site in our study was ZFX, in EPF; it was also observed in CAF, 
however the lower peak number in CAF meant that there was no statistically 
significant binding site identification in these cells. 
ZFX is a krueppel C2H2 -type zinc finger protein located on the X chromosome, 
with poorly defined physiological functions [64]. Studies have shown that ZFX 
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functions as a transcription factor [65] with the capacity to regulate self-renewal 
and cell survival in embryonic and haematopoietic stem cells [66, 67]. ZFX has 
been recognised as an oncogene in a number of cancers (reviewed in [68]). In 
prostate cancer cell lines, ZFX has been shown to drive cell proliferation and 
promote cell survival [69] and expression of ZFX has been shown to be elevated 
in prostate tumours [69, 70]. There is no known link between the functions of ZFX 
and AR. We have shown that ZFX mRNA and protein is expressed in AR positive 
prostate stromal cells and is co-expressed with AR in developing prostate 
mesenchyme. This suggests ZFX may associate with AR; however further study 
is required to address whether ZFX binds to and serves as a co-factor for AR. 
 
In conclusion, we have identified genome wide AR DNA binding in primary 
prostate fibroblasts and observed considerable differences with AR binding in 
tumour cells. We suggest that further verification of stromal AR binding patterns 
will eventually lead to a more complete and physiologically relevant 
understanding of AR action. 
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Figure Legends 
 
Figure 1 AR protein expression and genome-wide AR binding in prostate stromal 
fibroblasts.  (A) Western blot analysis of AR (110 kDa) and β-actin (42 kDa); 
male rat brain tissue at P0 and PC3 cells (negative controls), male rat epididymis 
and whole prostate tissue at P0 (positive controls), LNCaP, WPMY1-AR prostate 
fibroblast cell line, primary embryonic prostate fibroblasts (EPF) and primary 
prostate cancer-associated fibroblasts (CAF). β-actin was used as the loading 
control. * lysates diluted 1:100 with male rat brain tissue lysate at P0. 
Representative blot from 2 biological replicates and 2 technical replicates (n=4). 
(B) An overview of AR ChIP-seq peaks of WPMY1-AR, EPF and CAF cells 
detailing number of peaks called by MACS2.0 and Homer algorithms and final 
co-identified peak libraries used in subsequent analyses. (C) Genomic location 
analysis of AR peaks in EPF, CAF and WPMY1-AR cells in comparison to the 
whole genome (hg19). AR peaks were enriched (33-41%) within the promoter 
regions of genes (-1000bp to +100bp from the TSS) in all 3 cell types. (D) Venn 
diagram illustrating the overlap of AR peaks between WPMY1-AR, EPF and 
CAF. 783 peaks were co-identified in all 3 peak datasets. CAF had the lowest 
number of unique AR peaks (629) representing 27% of the total CAF peaks. 67% 
(1558) of CAF peaks were co-identified in EPF. EPF had the highest number of 
unique AR peaks (7534) representing 68% of the total EPF peaks. Abbreviations: 
5’UTR = 5’ untranslated region, 3’ UTR = 3’ untranslated region, TTS = 
translational termination site. 
 
Figure 2 Genome-wide AR binding differs between primary prostate fibroblasts 
and prostate cancer epithelium. (A) Genome-wide correlation of ChIPseq read 
coverage between primary embryonic prostate fibroblasts (EPF), prostate 
cancer-associated fibroblasts (CAF) and multiple prostate cancer epithelial cell 
lines (PCCLs). The heatmap shows the pairwise Spearman correlation coefficient 
based on read coverage of 10kb bins excluding signal artifact regions. (B) 
ChIPseq read coverage of PCCLs at primary fibroblast peak sites. Heatmaps 
show the mean ChIPseq read coverage of PCCLs between -2Kb and +2Kb from 
the centre (0Kb) of called EPF, CAF and PCCL called AR peaks. Heatmaps 
illustrate a paucity of ChIPseq read coverage of PCCLs at primary fibroblast AR 
binding sites (C) Genomic location analysis of AR peaks in cancer cells in 
comparison to the whole genome (hg19). Only 2.2% of AR peaks were enriched 
in the promoter regions of genes (-1000bp to +100bp from the transcriptional 
start site (TSS)) in PCCLs in comparison to 36.5 and 41.0% in EPF and CAF 
respectively. (D) Average ChIPseq read coverage of EPF, CAF and PCCLs 
centred around promoter regions of genes (-1000bp to +1000bp from the TSS) 
expressed as mapped reads per base pair per peak normalized per 1x107 reads. 
The histogram shows approximately 3-fold enrichment of EPF and 2-fold 
enrichment of CAF cells at TSSs compared to PCCLs. (E) Venn diagram 
illustrating the overlap of AR peaks between EPF, CAF and PCCLs. Only 0.35%, 
0.05% and 0.15% of epithelial AR peaks are co-identified in EPF, CAF and both 
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EPF and CAF respectively. Abbreviations: 5’UTR = 5’ untranslated region, 3’UTR 
= 3’ untranslated region, TTS = translational termination site. 
 
 
Figure 3 Identification of primary embryonic and cancer-associated prostate 
fibroblast AR cistromes. (A) Venn diagram illustrating the overlap of non- 
epithelial embryonic prostate fibroblast (EPF) and prostate cancer-associated 
fibroblast (CAF) AR peaks. 9466 AR peaks were identified as EPF-specific, 770 
AR peaks were identified as CAF specific and 1467 were co-identified in both 
fibroblast cell types (Fibroblast peaks) (B) Gene track examples of EPF-specific, 
CAF-specific and Fibroblast peaks at loci on chromosomes 2, 7 and 10 
respectively (hg19). (C) An overview of RNA-seq transcriptomes of EPF and CAF 
detailing the total number of reads sequenced, number of paired reads, number 
of reads mapped the hg19 genome and the total number of genes with read 
counts > 10 transcripts per million (TPM). (D) Transcript validation of genes 
associated with upstream AR peaks (between 0 to -100000bp upstream of the 
transcriptional start site (TSS)) from EPF-specific, CAF-specific and Fibroblast 
AR peak datasets. Venn diagrams illustrate 1560 unique genes with an EPF- 
specific upstream AR peak have read counts of > 10 TPM in the EPF RNA-seq 
transcriptome (43.0%). 112 genes with a CAF-specific upstream AR peak have 
read counts of > 10 TPM in the CAF RNA-seq transcriptome (33.1%). 208 genes 
with a Fibroblast upstream AR peak have reads counts of >10 TPM in both CAF 
and EPF RNA-seq transcriptomes (35.6%). Final EPF-specific cistrome contains 
1560 genes, CAF-specific cistrome contains 112 genes and Fibroblast cistrome 
contains 208 genes. 
 
Figure 4 AR peak distribution differs within the promoter regions of genes 
between primary prostate fibroblasts and prostate cancer in vitro epithelium and 
in vivo tissues. (A) Genomic location analysis of EPF-specific, CAF-specific, 
fibroblast, WPMY1-AR, PCCLs and prostate cancer in vivo tissue (PCa in vivo) 
AR peaks upstream of gene transcriptional start sites (TSS). 28%, 38% and 34% 
of upstream AR peaks were located in proximal promoter regions of genes 
(+100bp to -1kb from the transcriptional start sites of genes (TSS)) in EPF- 
specific, CAF-specific and fibroblast respectively. This AR binding distribution 
was conserved in WPMY1-AR control fibroblast cell lines with 63% of upstream 
AR peaks in proximal promoter regions. Only 4% and 19% of upstream AR 
peaks were located in proximal promoter regions of genes in PCCLs and PCa in 
vivo tissues respectively. (B) Genomic location analysis of transcript-validated 
EPF-specific, CAF-specific and fibroblast AR peaks upstream of gene TSSs. 
Enrichment of AR binding at proximal promoter regions of genes was conserved 
in AR peaks which have been validated with RNAseq transcript expression. 
 
Figure 5 Identification of AR cistrome targets within in vivo prostate tissue 
datasets. (A) Venn diagrams illustrating the overlap of primary embryonic 
prostate fibroblast-specific (EPF-specific), primary prostate cancer-associated 
fibroblast-specific (CAF-specific) and Fibroblast AR peaks with multiple in vivo 
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prostate cancer (PCa in vivo) AR peaks. Between ~22-30% of the cell AR peaks 
were co-identified in PCa in vivo tissue AR peaks with an overlap of 2021, 171 
and 452 EPF-specific peaks , CAF-specific peaks and Fibroblast peaks 
respectively. (B) Venn diagrams illustrating the overlap of EPF-specific, CAF- 
specific and Fibroblast AR cistromes with the human embryonic prostate tissue 
transcriptome (EMB transcriptome). Between ~82-86% of the AR cistromes were 
co-identified in the EMB transcriptome with an overlap of 1350, 94 and 172 with 
EPF-specific, CAF-specific and Fibroblast cistromes respectively. (C) Venn 
diagrams illustrating the overlap of EPF-specific, CAF-specific and Fibroblast AR 
cistromes with microdissected PCa in vivo stroma-specific transcripts (PCa 
stromal-specific, GSE20758, [57]) and PCa stromal-enriched transcripts (PCa 
stromal-enriched, GSE8218 and GSE17951,[58]) following removal of transcripts 
not present on the arrays. For the stromal-specific transcripts, 61 and 477 were 
co-identified with the EPF-specific cistrome, 6 and 32 were co-identified with the 
CAF-specific cistrome and 7 and 59 were co-identified with the Fibroblast 
cistrome. 
 
Figure 6 Comparison of AR cistrome targets to androgen regulated transcripts 
within in vivo prostate tissue datasets. (A) Venn diagrams illustrating the overlap 
of EPF-specific, CAF-specific and Fibroblast AR cistromes with androgen- 
responsive transcripts from the embryonic mouse urogenital sinus (UGS DHT- 
regulated, [3]). Between ~9-12% of the AR cistromes were co-identified with 
androgen-responsive UGS transcripts with an overlap of 188, 14 and 20 with 
EPF-specific, CAF-specific and Fibroblast cistromes respectively. (B) Venn 
diagrams illustrating the overlap of EPF-specific, CAF-specific and Fibroblast AR 
cistromes with transcripts that are differentially expressed following androgen- 
deprivation treatment in human prostate cancer tissue samples (PCa ADT 
responsive) and in human normal adjacent tissues (Benign ADT responsive). 
Between ~6-8% of the AR cistromes were co-identified with PCa ADT responsive 
transcripts with an overlap of 88, 6 and 16 with EPF-specific, CAF-specific and 
Fibroblast cistromes respectively. Between ~11-13% of the AR cistromes were 
co-identified with Benign ADT responsive transcripts with an overlap of 159, 13 
and 23 with EPF-specific, CAF-specific and Fibroblast cistromes respectively. 
 
Figure 7 Identification of ZFX as a potential AR co-factor in primary prostate 
fibroblasts. (A) Consensus sequence logos of the top sequence motifs and their 
significance identified in primary prostate embryonic fibroblast (EPF), primary 
prostate cancer-associated fibroblast (CAF) and WPMY1-AR using de novo motif 
analysis with HOMER. * p<1E-50. Classical androgen-response element 
sequence (ARE) is provided for comparison. (B) An overview of the number of 
AR ChIPseq peaks containing the top sequence motif, the best match 
transcription factor (TF) based on positive mRNA expression from RNAseq 
analysis and expression value in transcripts per million (TPM). (C) Histogram 
showing the percentage (bold) of ChIPseq peaks positive for the classical ARE in 
EPF, CAF, WPMY1-AR, prostate cancer cell lines (PCCL) and prostate cancer 
tissues (PCa). EPF and CAF had 100-fold less and WPMY1-AR 10-fold less ARE 
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positive peaks than PCCLs. (D) Localization of AR and ZFX in serial sections of 
P0 male urogenital tract by immunohistochemistry. Ur denotes urethra, UrSM 
denotes urethral smooth muscle, VP denotes ventral prostate, DP denotes dorsal 
prostate, VPE denotes epithelial buds of the ventral prostate and VPM denotes 
ventral prostate mesenchyme. (i-ii) P0 male UGT showed AR expression 
localized to VP mesenchymal cells and little or no expression in epithelial cells of 
the VP prostatic buds (low magnification i, high magnification ii). (iii-iv) ZFX 
expression was localized to both VP mesenchyme and in the epithelium of 
prostatic buds but appeared more nuclear in VP mesenchyme. (low magnification 
iii, high magnification iv). Negative control omitting primary antibody inset (iii-iv). 
Left panels x 8 magnification, scale bars = 300μm and right panels at x 40 
magnification, scale bars = 60μm. 
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1. Genome-wide distribution of AR defined in primary prostate stromal cells using ChIPseq 
 
2. Stromal AR shows non-ARE binding sites with a unique distribution in stroma compared to 
tumour cells 
 
3. Frequent localisation of AR proximal to transcriptional start site in stroma 
 
4. Deconvolution of stromal AR binding sites in prostate tumour tissue ChIPseq datasets 
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